The World Health Organization is “very worried” about the spread of a severe form of mpox that has killed nearly 600 people, mainly children, in the Democratic Republic of Congo this year, a senior official said.
The World Health Organization on Thursday said several contaminated syrups and suspension medicines had been identified in countries in the WHO regions of the Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific.
White House officials on Tuesday met with representatives of Sanofi, AstraZeneca, and Thermo Fisher “and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market,” the White House said in a statement.
“We like to tease that market access is an overnight sensation 20 years in the making. But in all seriousness, market access has always been ultra-important to those of us working in the space, so it’s rewarding to see greater recognition across the industry.” Andrew Gottfried, CEO of Entrée Health, discusses one of the most important and hottest topics in pharma today: market access.
In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.
The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.
Following a nine-month review, the Biden administration will issue a framework for the National Institutes of Health to implement so-called “march-in rights” under the Bayh-Dole Act of 1980.
The finger-prick blood collection device could provide a less-invasive option for some commonly ordered lab tests.
Like the quest to discover a new medicine, pulling off a successful mega-deal is a frustrating and elusive experiment. Tokyo-based drugmaker Takeda understands the difficulty of both. Although boss Christophe Weber will have plenty to celebrate on the upcoming fifth anniversary of his landmark $62 billion Shire acquisition, the deal has delivered no value to his shareholders.
A review of the latest leadership moves in the pharma industry.
